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Abstract 
Papillon-Lefèvre (PLS, OMIM: 245000) is a rare disease characterized by severe 
periodontitis and palmoplantar keratoderma. It is caused by mutations in both alleles of the 
cathepsin C (CatC) gene which completely abrogate the proteolytic activity of this cysteine 
protease. A genetic analysis most often is unaffordable or unavailable to establish an early 
rapid diagnosis of PLS. In this study, we tested the hypothesis that active CatC is 
constitutively excreted and can be easily traced in the urine of normal subjects. If true, its 
absence in the urine of PLS patients would be an early, simple, reliable, low cost and easy 
diagnostic technique. All 75 urine samples from healthy control subjects (aged 3 months to 80 
years) contained proteolytically active CatC and its proform as revealed by kinetic analysis 
and immunochemical detection. From the urine samples of 31 patients with a PLS phenotype, 
29 contained neither proteolytically active CatC nor the CatC antigen so that the PLS 
diagnosis was confirmed. CatC was detected in the urine of the other two patients, but genetic 
analysis revealed no loss-of-function mutation in the CatC gene indicating that they suffer 
from a PLS-like syndrome but not from PLS. Urinary test strips impregnated with a sensitive, 
easy detectable CatC substrate in conjunction with a CatC capture antibody may now be 
designed to allow any laboratory worldwide to establish a reliable diagnosis of PLS and 
monitoring disease predisposition soon after birth.    
 
Keywords: Papillon-Lefèvre Syndrome (PLS), diagnostic method, cathepsin C, inherited disorder, 
urine analysis,  
 
Abbreviations: CatC, cathepsin C; PLS, Papillon-Lefèvre syndrome, APN, aminopeptidase N; AMC, 
aminomethylcoumarin 
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INTRODUCTION 
Papillon-Lefèvre syndrome (PLS, OMIM: 245000) is a rare inherited autosomal 
recessive disorder characterized by palmoplantar hyperkeratosis and an early and severe 
periodontitis, causing loss of both the primary and permanent teeth. The prevalence of PLS is 
1 to 4 cases per million people and the carrier rate is 2 to 4 per 1000. There is no gender 
predilection but parental consanguinity has been reported in more than 50% of cases 1,2. 
Palmoplantar keratoderma may be visible at birth or 1 to 2 months thereafter, but generally, 
keratoderma and periodontitis develop in parallel between the 6th month and the 4th year of 
life of the patient, and often coincide with the eruption of the first teeth 3. Other symptoms 
can also occur such as mental retardation, intracranial calcifications, recurrent skin infections, 
hyperhidrosis and liver abscesses 2,4. The disease-causing gene, cathepsin C (CatC) (CTSC) 5,6 
is located on chromosome 11q14-217-9. To date, 75 mutations have been reported for PLS 
patients, of which 68% were homozygous for one dysfunctional allele. Fifty percent of 
homozygous mutations were missense, 25% nonsense, 23% frameshift, and 2% were other 
types of mutations 10. In addition to the classic form of PLS, 6 cases with late-onset 
periodontal disease and/or late-onset palmoplantar-lesions were reported 11. Haim-Monk 
syndrome, allelic to PLS has been described in a Jewish community in India, with 
arachnodactyly, acroosteolysis and onychogryphosis as additional features 13. The diagnosis 
of PLS is based on clinical signs and is generally confirmed by exon sequencing. This latter 
procedure, however, has several drawbacks, the relatively high costs in comparison to the low 
socio-economic status of the patients from countries with frequent intrafamilial marriages, the 
uncertain interpretation of rare benign mutations and/or the unavailability of an appropriate 
platform for DNA preparation and sequence analysis 14,15.  
CatC, also known as dipeptidyl peptidase I (DPPI, EC 3.4.14.1) is a lysosomal 
cysteine exopeptidase belonging to the papain superfamily of cysteine peptidases 16. The gene 
encoding CatC spans over 46 kb (NM_001814.4) and contains seven exons 6,17. Functional 
CatC is a tetrameric enzyme consisting of four identical subunits linked together by non 
covalent bonds with a total molecular mass of approximately 200 kDa. Each subunit is 
composed of three polypeptide chains: a N-terminal fragment or exclusion domain (~13 kDa), 
a heavy chain (~23 kDa) and a light chain (~7 kDa) 18. CatC subunits are synthetized as single 
chain pro-enzymes of about ~60 kDa that can be rapidly processed during biosynthesis in 
certain cell types. Processing and complete maturation requires the removal of a 15 kDa 
internal propeptide and intramolecular cleavages by other proteases19. The regulation of this 
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processing however is still unknown. CatC is expressed mostly in the lung, spleen, kidney, 
liver and myeloid cells like neutrophils, macrophages and their precursors 17. It has an 
important role in the activation of various granular serine proteinases from neutrophils 
(elastase-like proteinases), mast cells, cytotoxic T-lymphocytes and natural killer cells 20.  
We have recently shown that a proteolytically active CatC is secreted by activated 
neutrophils in lung fluids from patients with chronic inflammatory lung diseases, which 
makes it a marker of neutrophilic lung inflammation (Hamon et al., in preparation)1. We also 
observed that proCatC, but not the mature protease, was secreted by bronchial epithelial cells 
(Hamon et al., in preparation) and that MCF-7 epithelial cells secrete both mature and 
proCatC (unpublished). In the present study, we hypothesize that urinary tract and/or renal 
epithelial cells also produce CatC constitutively in healthy individuals; if true, CatC should be 
absent in the urine of PLS patients, and monitoring CatC in the urine could be utilized as an 
early, simple, reliable, low cost diagnostic technique for PLS.  
 
MATERIALS AND METHODS 
Reagents 
Recombinant CatC and aminopeptidase N (APN) were from Unizyme Laboratories 
(Hørsholm, Denmark) and R&D systems (Lille, France), respectively. AntiCatC antibodies 
were used in this study included: the mouse monoclonal anti-CatC Ab (Ab1) (Santa Cruz 
Biotechnology, Heidelberg, Germany), the goat polyclonal anti-CatC Ab (Ab2) (R&D 
Systems) and the goat polyclonal anti-CatC (Ab3) (Everest Biotech, Oxforshire, UK). The 
mouse monoclonal anti-APN Ab was from Santa Cruz Biotechnology. Gly-Phe-AMC was 
from Enzyme Systems Products (Illkirch, France) and H-Ala-AMC was supplied by Bachem 
(Weil am Rhein, Germany). The cysteine protease inhibitor E-64c ((2S,3S)-trans-
Epoxysuccinyl-L-leucylamido-3-methylbutane)) was from Sigma-Aldrich (St Louis, MO, 
USA) and the specific inhibitor of CatC, Thi-Phe-CN ((β-2-thienyl)-L-alanyl-L-phenylalanine 
nitrile) was provided by Dr Lesner (University of Gdansk, Poland). EDTA or 
Ethylenediaminetetraacetic acid was from Merk (Darmstadt, Germany) and the specific 
inhibitor of APN, bestatin was from Santa Cruz (Heidelberg, Germany). 
 
Urine collection 
                                                          
1
 Neutrophilic mature cathepsin C is generated by a multi-step proteolytic process and secreted by 
activated cells during inflammatory lung diseases. 
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Urine samples were collected from 31 PLS patients from European countries (France, 
Germany, UK, Hungary, Italy and Turkey), Asian Countries (China, India, Iran, Saudi 
Arabia) and from the USA.  The 75 healthy volunteers were from France and Iran. The study 
protocol was approved by the Comité de Protection des Personnes, CPP OUEST-1, Tours, 
France, and informed consent was obtained from each individual prior to enrollment. 
Demographics and clinical data from patients are summarized in Table I. After centrifugation 
(3000 g, 15 min) at 4°C to eliminate cells and debris, the urine supernatants were 
concentrated 20 or 120 times using Vivaspin 15R concentrators (molecular mass cutoff, 
10 kDa; Sartorius, Goettingen, Germany) and store at 4°C.  
 
Western blotting analysis 
Briefly, urine samples were electrophoretically separated on a 10% SDS-PAGE in 
reducing conditions for CatC analysis and in non-reducing conditions for APN analysis, and 
then transferred to a nitrocellulose membrane (Amersham Biosciences, Uppsala, Sweden). 
After saturation, membranes were incubated with anti-CatC Abs (Ab1 and Ab3 diluted 1:500; 
Ab2 diluted 1:1000) or with anti-APN mAb (diluted 1:500). After washing, membranes were 
incubated with peroxidase-conjugated anti-mouse IgG (diluted 1:10000) or anti-goat IgG Abs 
(diluted 1:20000) (Sigma-Aldrich), when appropriate. Bound Abs were detected by 
chemiluminescence (ECL Plus Western Blotting Kit Detection Reagents, GE Healthcare, UK) 
according to the manufacturer’s instruction. 
 
Enzyme assays 
Assays were carried out at 37°C in 50 mM sodium acetate, 30 mM NaCl, 1 mM 
EDTA, 2 mM DTT, pH 5,5 for CatC and in 50 mM Tris, pH 7 for APN. Proteolytic activity 
was measured using 5 µL of urine supernatants with 30 µM Gly-Phe-AMC in a total volume 
of 60 µL for CatC or with 50 µM H-Ala-AMC in a total volume of 100 µL for APN 
(excitation wavelength = 340 nm, emission wavelength = 460 nm; Spectramax Gemini 
(Molecular Devices, Sunnyvale, CA, USA)). The presence of CatC in urine was controlled 
incubating urine samples with the selective CatC inhibitor Thi-Phe-CN 23  prior to substrate 
addition.  Recombinant CatC and APN were used as controls, respectively. For some 
experiments, urine samples were preincubated with 100 µM E64c, 5 µM Thi-Phe-CN, 5 mM 
EDTA or 100 µM bestatin for 30 min at 37°C prior the measurement of the proteolytic 
activity. 
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Cell culture 
Human urinary bladder cancer T24 and T24M cells (Biotechnology Division, 
Biomedical Research Foundation, Academy of Athens, Greece) were cultured in McCoy's 5A 
Medium with L-glutamine (Ozyme, Saint Quentin en Yvelines, France) supplemented with or 
without 10% fetal calf serum (FCS) at 37 °C. Madin-Darby Canine Kidney Epithelial Cells 
(MDCK) were cultured in Eagle's Minimum Essential Medium supplemented with or without 
10% fetal calf serum (FCS) at 37 °C. Cells were lysed in PBS containing 0.5% nonidet P-40 
(IGEPAL 630), and after centrifugation (10000 g, 15 min at 4°C), the lysate was stored at -
20°C. Cell supernatants were concentrated 30 times using Vivaspin 15R concentrators 
(molecular mass cutoff, 10 kDa; Sartorius). Proteins in lysates and in supernatants were 
quantified with a bicinchoninc acid assay (BCA) (Thermo Scientific, Rockford, IL, USA). 
 
Genetic investigations 
Patient’s genomic DNA and when available parents DNA was extracted from EDTA 
blood samples with the automated method EVO®100 ReliaPrep (Tecan, Promega). 
PCR and sequencing reaction: The in vitro amplification and sequencing of all CTSC exons 
and intron–exon boundaries were performed as described in 21 with minor modifications: 
sequencing was carried out using Big Dye Terminator v3.1 on a 3500xL Dx Genetic Analyzer 
(Applied Biosystems, ThermoFisher St Aubin, France). The in silico analysis of missense 
mutations and  the database queries were conducted through the Alamut Interface (Alamut® 
Visual v2.3, interactive biosoftware, Rouen, France)). Mutations were described in 
accordance with the CTSC cDNA sequence GenBank NM_001814.2 and HGVS 
recommendations. 
Deletion search was performed using custom array CGH: custom microarrays (8 × 60K) were 
designed with e-array web software (Agilent Technologies, CA) using the Similarity Score 
Filter in order to select highly specific probes. A total of 3141 probes were distributed: about 
one probe every 100 bp in the CTSC gene and 50 Kb around the gene then one probe every 
350 bp in the 300 Kb regions apart. DNA was labelled (cyanine 3 or cyanine 5) using the Sure 
Tag DNA labeling kit from Agilent Technologies and hybridized onto the microarrays 
according to the manufacturer’s instructions. DNA was analyzed in comparative genomic 
hybridization experiments with fluorochrome swapping, in a trio along with DNA from two 
subjects not affected by the PLS. Scanning of the microarrays was performed using a 
G2565CA scanner (Agilent Technologies). Data analysis was carried out with softwares from 
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Agilent Technologies, namely Feature Extraction 10.7.3.1 and Agilent Genomic Workbench 
6.0.130.24.  
 
RESULTS  
Pro and mature CatC in urine of healthy subjects 
 We first screened 20-fold concentrated urine samples from 75 healthy individuals of 
various ages ranging from 3 months to 80 years for the presence of CatC.  Using three 
different commercial antibodies (Ab1, Ab2, Ab3) to CatC we found that Ab1 and Ab3 
recognized two different epitopes of the heavy chain whereas Ab2 recognized one epitope in 
the propeptide region. We observed two immunoreactive bands with an apparent molecular 
mass of ~23 kDa and ~60 kDa in 100% of the urine samples. These bands corresponded to the 
heavy chain of mature CatC and to proCatC respectively (Figure 1). The presence of pro and 
mature CatC did not vary with the timepoint of urine sampling, with the age and sex of the 
donor (Figures 2A&B). All of the 75 urine samples hydrolyzed the CatC substrate Gly-Phe-
AMC and all peptidic activities were fully inhibited by the CatC nitrile inhibitor Thi-Phe-CN 
(Figure 2C). Based on the rate of hydrolysis of Gly-Phe-AMC by recombinant CatC, we 
estimated the concentration of active CatC to be in the 1-10 nanomolar range in normal urine. 
We did not observe any pro or mature CatC in plasma by immunoblotting (data not shown). 
Plasma-derived CatC, moveover, would hardly be expected to cross the kidney filtration 
barrier because of its large tetrameric Mr of ~200 kDa. We found however that human bladder 
cells (T24/T24M) and canine kidney epithelial cells (MDCK) produced and secreted proCatC 
but not the mature protease (not shown). To learn whether proCatC is converted into active 
CatC in urine, we compared the ratio between proCatC and fully processed and active CatC in 
a urine sample before and after a 24h incubation time at 37°C. No change in this ratio was 
observed strongly suggesting that proCatC processing active proteinases do not occur in urine 
(data not shown).    
 
CatC in urine of patients with a PLS phenotype 
31 urine samples were collected from clinically diagnosed or suspected PLS patients 
from different European, American and Asian countries (Table I). Urine samples were 
centrifuged upon receipt, concentrated (x120) and analyzed for the presence and activity of 
CatC as described for control subjects (Figure 3A). A sequencing-based PLS diagnosis was 
previously established for 21 patients allowing the identification of either nonsense, frameshift 
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or missense mutations in the CTSC gene (Table I). In spite of the greater concentration of PLS 
urine samples (x120 vs x20 in controls) no pro or active CatC was detected in any of these 
patients whatever the type of mutation was (Table I). We used the measurement of 
aminopeptidase N activity as a positive control to check the quality of the urine sample (data 
not shown). Of the 10 remaining patients whose PLS diagnosis was only based on clinical 
features (Table I) eight had no pro or mature CatC in their urine and we confirmed the PLS 
diagnosis by a genetic analysis allowing detection of the mutation (Table I, Figure 3). The 
other two patients, however, had pro and mature CatC in their urine. The first patient was a 
20-year-old Turkish boy (P#30) who presented the classical dental and dermatologic 
characteristics of PLS 24. He also had a bilateral, hypertrophic-looking corneal leukoma and 
was suspected to suffer from PLS but no genetic analysis had been performed so far. A 
detailed genetic analysis was therefore performed, but no mutation of the CatC gene was 
found indicating that he did not suffer from classical PLS. The second CatC positive patient 
was a 16-year-old French teenager (P#31) who presented anomalies of deciduous teeth and 
had developed a palmoplantar psoriasiform skin changes with tapered distal phalanges as 
observed in Haim-Munk syndrome (Figure 4A&B). Again, the genetic analysis did not reveal 
a loss-of-function mutation in the CatC gene but one homozygous CTSC polymorphism. 
Urinary CatC activity was fully inhibited by the specific CatC inhibitor Thi-Phe-CN (data not 
shown). At least one of these polymorphisms came from his father but his mother presented a 
periondontitis and anomalies of deciduous teeth (Figure 4C). The urine of the mother also 
contained pro and mature CatC (Figure 4D). Mature CatC was present in a lysate of white 
blood cells from the son and his mother, and it compared with that of a healthy subject. 
Further, proteolytically active elastase-like proteases were present in white blood cell lysates 
indicating that functional CatC was present in cells and tissues (data not shown). 
 
DISCUSSION  
 Clinical signs of the classical PLS become apparent by the age of one to five years 
when dry, scaly patches appear on the skin of palms and soles, and severe inflammation starts 
to affect the surrounding gingiva and bone of primary teeth, leading to their rapid lost. The 
genetic etiology of PLS has been clearly established but it still remains unclear why a lack of 
CatC activity leads to specific dermatological lesions and severe destructive periodontitis on 
the long run. A plausible explanation for the development of chronic periodontitis is the 
deficiency of the antimicrobial peptide LL-37 in the gingiva, allowing for infection with A. 
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actinomycetemcomitans and the development of severe periodontal disease 25. Proteinase 3 
and possibly other neutrophil serine proteases release this peptide or similar peptides like 
FALL-39 from a precursor molecule after neutrophil activation. All these serine proteases 
together with CatC are missing in PLS patients. On the other hand, mutations in completely 
different genes may induce a PLS-like syndrome with similar dermatological lesions and 
destructive periodontitis, but may be very different with regard to co-morbidities and optimal 
treatment regimens 26. Several sporadic cases with a PLS-like clinical phenotype have been 
reported in the literature (refs) and two examples of a PLS-like syndrome have been included 
in this study. Because of the variable manifestations of the classical PLS syndrome, its overlap 
with other clinical entities and the potential occurrence of mild forms of PLS, gene-related 
functional and biochemical assays are of high value for the diagnosis of PLS and may help to 
discover atypical cases of PLS that otherwise cannot be discerned by exon sequencing alone. 
PLS may be underdiagnosed and more prevalent than documented at present 27.  
CatC is expressed as a pro-proteinase by epithelial and myeloid cells and their 
precursors and is activated by a multistep mechanism possibly involving several proteinases 
5,17,22
. Thus pro- and/or mature CatC may be constitutively present in a variety of cells and 
tissues including renal and/or bladder epithelial cells. Here we evaluated the hypothesis that 
urine from healthy and diseased persons is in fact a reliable source of pro- or active CatC that 
can be easily characterized and analyzed for by enzymatic and/or immunochemical methods. 
In this study, we found that the absence of active CatC and its proform in the urine was a 
strong and reliable indicator for PLS and of great value for the early diagnosis of PLS. 
Absende of urinary CatC protein or activity was always associated with loss-of function-
mutations in the CatC gene. By contrast 100% of our urine samples from control subjects of 
any age and gender contained measurable amounts of active CatC. The easy availability of 
large volumes of urine is advantageous from multiple perspectives in comparison to saliva or 
gingival crevicular fluids which only contain very little quantities of CatC activity in healthy 
subjects (ref). The implementation of an early treatment regimen can clearly stop the 
progression of periodontitis and skin lesions and can improve the quality of life of a PLS 
patient as  highlighted in a recent case report 28. Demonstrating the absence of urinary CatC 
activity soon after birth and before the outbreak of clinical symptoms can be used as a 
screening procedure for PLS in populations with a high frequency of intra-familial marriages 
and in individuals who are closely related to a PLS patient. A test based on the absence of 
urinary CatC activity will allow to clearly distinguish between patients having loss-of-
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function mutations in their CTSC gene, including PLS and Haim-Munk syndrome, and other 
patients with a PLS-like phenotype who suffer from another, so far unidentified syndrome.   
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FIGURE LEGENDS 
 
Figure 1: CatC in urine from healthy subjects. Immunoblots of 20 fold-concentrated 
samples of urine collected from healthy control subjects, using different  anti-CatC 
antibodies;  Ab1 recognizes an epitope on the heavy chain (A); Ab2 is directed to the 
propeptide region (B); Ab3 binds  to another epitope on the heavy chain of CatC (C). 
Recombinant CatC was used as a control (left lane). 
 
Figure 2: Continuous presence of CatC in urine from healthy children and adults. (A) 
Immunoblots of 20 fold-concentrated samples of urine collected from healthy children at the 
age of 3 months (3 mo), 1 year (1 yr) and 3 years (3 yr) compared to a healthy adult, using 
anti-CatC Ab1. (B) Immunoblots of 20 fold-concentrated samples of urine collected at 
different times of the day from one healthy woman and one healthy man, using anti-CatC 
Ab1. Recombinant CatC was used as a control. (C) CatC activity in 20 fold-concentrated 
urines from 50 healthy control subjects using the fluorogenic substrate Gly-Phe-AMC (30 
µM) and its inhibition by E64c (100 µM) and Thi-Phe-CN (5 µM). 
 
Figure 3: Absence of CatC in urine from a PLS patient. (A) Protocol for analysis of 
urinary CatC. After receipt of PLS samples, urines were centrifuged to eliminate cells and 
debris, and then concentrated 120 times, six times more than the urine of healthy subjects, to 
analyze the presence and the proteolytic activity of CatC as described in the materials and 
methods section. Immunoblots of 20 fold-concentrated samples of urine collected from two 
healthy control subjects (controls Ct1 and Ct2) and of 120 fold-concentrated samples of urine 
collected from one representative PLS patient (P#23), using anti-CatC Ab1 (B), Ab2 (C) and 
Ab3 (D). Recombinant CatC was used as a control. (E) CatC activity in 20 fold-concentrated 
urines from one healthy control subject (Ct1) and of 120 fold-concentrated samples of urine 
collected from one representative PLS patient (P#23) using the fluorogenic substrate Gly-Phe-
AMC (30 µM). 
 
Figure 4: Presence of CatC in urine from an atypical French patient without CTSC 
mutation. (A) Pedigree of suspected 16 yr-old individual (P#31) with suspected PLS. (B) The 
dermatological and dental features of the patient (P#31) and his mother. (C) Immunoblotting 
analysis with anti-CatC Ab1 of 120 fold-concentrated urines from the patient (P#31) 
compared to 20 fold-concentrated urines from a healthy control subject (Ct). (D) Western 
blotting of white blood cell lysates from the P#31 patient, his mother and a healthy control 
subject (Ct) using anti-CatC Ab1. Recombinant CatC was used as a control. 
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TABLE I 
Demographic and clinical data of patients with a PLS phenotype 
Patients Ethnicity Gender Age Clinical manifestations Mutation Urinary CatC 
  
       Pro 
CatC 
Mature  
CatC 
P#1 French  F 55 Palmoplantar hyperkeratosis, 
severe periodontitis 
c.96T>G (a) 
(p.Y32X) 
Nonsense 
- - 
P#2 Indian M 15 Transgradient palmoplantar 
keratoderma,  periodontitis 
c.912C>A (1) 
(p.Y304X) 
Nonsense 
- - 
P#3 Hungarian F 4 Palmoplantar hyperkeratosis, 
periodontitis 
c.681delCATACAT (2) 
(p.T188fsX199) 
Frameshift 
- - 
P#4 Hungarian F 13 Palmoplantar hyperkeratosis, 
severe periodontitis 
c.681delCATACAT (2) 
(p.T188fsX199) 
Frameshift 
- - 
P#5 Pakistanian F 14 Palmoplantar hyperkeratosis, 
periodontitis 
(p.W433L) (3) 
Missense 
- - 
P#6 Pakistanian M 9 Palmoplantar 
hyperkeratosis,periodontitis 
cerebral abscess 
c.815G>C (4) 
(p.R272P) 
Missense 
- - 
P#7 Pakistanian M 15 Palmoplantar hyperkeratosis, 
periodontitis 
c.815G>C 
(p.R272P) 
Missense 
- - 
P#8 Pakistanian F 15 Transgradient palmoplantar 
keratoderma,periodontitis 
c.815G>C 
(p.R272P) 
Missense 
- - 
P#9 Italian  F 42 Palmoplantar hyperkeratosis, 
severe periodontitis 
c.1141delC (5) 
(p.L381fsX393) 
Frameshift 
- - 
P#10 Hungarian F 12 Palmoplantar hyperkeratosis, 
severe periodontitis 
c.901G>A (6) 
(p.G301S) 
Missense 
- - 
P#11 Hungarian F 4 Palmoplantar hyperkeratosis, 
severe periodontitis 
c.901G>A (6) 
(p.G301S) 
Missense 
- - 
P#12 Erythrean M 12 Palmoplantar hyperkeratosis, 
severe periodontitis, Tinea 
capitis 
c.755A>T (7) 
(p.Q252L) 
Missense 
- - 
P#13 Erythrean M 15 Palmoplantar hyperkeratosis, 
severe periodontitis 
c.755A>T (7) 
(p.Q252L) 
Missense 
- - 
P#14 Moroccan M 19 Mild palmoplantar 
hyperkeratosis, severe 
periodontitis 
c.854C>T (8) 
(p.P285L) 
Missense 
- - 
P#15 Moroccan M 35 Palmoplantar hyperkeratosis, 
severe periodontitis, 
edentulous by now 
c.854C>T (8) 
(p.P285L) 
Missense 
- - 
P#16 German F 24 Palmoplantar hyperkeratosis, 
severe periodontitis, 
edentulous by now 
c.566-572Del (9) 
(T189FS199X) 
Frameshift 
- - 
P#17 German M 48 Severe palmoplantar 
hyperkeratosis, late onset of 
comp. heterozygous (10) - - 
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P#12 and P#13 / P#14 and P#15 are brothers 
P#3 and P#4 are sisters 
P#24, P#25 and P#26 are in the same family 
(a)/identified in this work 
(1) Ragunatha et al., 2014 
(2) Farkas et al., 2013 
(3)  
(4) Kanthimathinathan et al., 2013 
(5) Bullon et al., 2013 
(6)  
(7) Schacher  et al., 2006 
(8) Noack  et al., 2008 
(9) Rüdiger et al., 1999 
(10) Noack et al., 2008 
(11) Xinwen et al., 2015 
severe periodontitis (22 
years of age), liver abscess 
c.322A>T/c.436delT 
(p.K108X/p.S146fs153X) (10) 
Nonsense / Frameshift 
P#18 German M 27 Palmoplantar hyperkeratosis, 
severe periodontitis 
comp. heterozygous (10) 
c.947T>G (pL316R) 
c.1268G>C (pW423S) 
Missense 
- - 
P#19 Chinese M 22 Palmoplantar psoriasiform 
appearance, severe 
periodontitis 
c.394 C>G (11) 
(p.R132G) 
Missense 
- - 
P#20 Chinese M 22 Palmoplantar psoriasiform 
appearance, severe 
periodontitis 
c.394 C>G (11) 
(p.R132G) 
Missense 
- - 
P#21 Mauritian  M 5 Palmoplantar hyperkeratosis, 
severe periodontitis 
n.i - - 
P#22 Mauritian F 15 Palmoplantar hyperkeratosis, 
severe periodontitis 
n.i - - 
P#23 Puerto Rican F 31 Palmoplantar hyperkeratosis, 
severe periodontitis 
c.116G>C (a) 
(p.W39S) 
Missense 
- - 
P#24 Persian F 33 Palmoplantar hyperkeratosis, 
severe periodontitis 
c.815G>C (a) 
(p.R272P) 
Missense 
- - 
P#25 Persian M 9 Palmoplantar hyperkeratosis, 
severe periodontitis 
c.815G>C (a) 
(p.R272P) 
Missense 
- - 
P#26 Persian M 4 Palmoplantar hyperkeratosis, 
severe periodontitis 
c.815G>C (a) 
(p.R272P) 
Missense 
- - 
P#27 Saudi 
arabian 
M 17 Palmoplantar hyperkeratosis, 
severe periodontitis 
c.815G>C (a) 
(p.R272P) 
Missense 
- - 
P#28 Saudi 
arabian 
M 24 Palmoplantar hyperkeratosis, 
severe periodontitis 
c.815G>C (a) 
(p.R272P) 
Missense 
- - 
P#29 Pakistanian M 3 Palmoplantar hyperkeratosis, 
severe periodontitis 
n.i - - 
P#30 Turkish M 20 Palmoplantar hyperkeratosis, 
severe periodontitis,  corneal 
leukoma 
No mutation (a) + + 
P#31 French M 16 Palmoplantar psoriasiform 
appearance,  anomalies of 
deciduous teeth with no net 
periodontitis 
No mutation (a) + + 
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